Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 plus high-dose cytarabine and idarubicin in relapsed/refractory AML after standard-dose cytarabine induction failure
2009-013669-25Phase 2Terminated
- Sponsor
- Aegera Therapeutics
- Start
- Oct 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AEG35156 in acute myeloid leukemia (AML) (2 arms), sponsored by Aegera Therapeutics. Primary endpoints: Combined complete remission rate (CR and CRi) and Overall survival. Started Oct 2009; status: terminated.
02
Drugs
AEG35156
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-013669-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013669-25.